Bristol-Myers Squibb’s Acquisition of Kosan Biosciences

Bristol-Myers Squibb Company and Kosan Biosciences Inc. announced that the companies have signed a definitive merger agreement providing for the acquisition of Kosan by Bristol-Myers Squibb for approximately $190 million in cash. Kosan is a public company that develops cancer therapeutics. Cravath is representing Bristol-Myers Squibb in this transaction. The lawyers involved in the matter were partners Ronald Cami and Susan Webster and associates Assaf Oz and David W. Azarkh on corporate matters; partners Michael L. Schler, Stephen L. Gordon and Lauren Angelilli and associate Sophie Alexane on tax matters; and partner Elizabeth L. Grayer on antitrust matters. The deal was announced on May 29, 2008.